Results 251 to 260 of about 775,266 (372)

A multicentre registry of hospitalized patients with acute and chronic heart failure: Study design of the H2‐registry

open access: yesESC Heart Failure, EarlyView.
The H2‐Registry: overview, first results and outlook. Abstract Aims Heart failure (HF) is a highly prevalent condition affecting 1–3% of the adult population in Europe. Despite landmark improvements in HF care over the last two decades, hospitalization and mortality rates remain relatively high.
Johannes Leiner   +15 more
wiley   +1 more source

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

open access: yesESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel   +9 more
wiley   +1 more source

Acute myocarditis according to age: Presentation, management and early outcomes

open access: yesESC Heart Failure, EarlyView.
MIS, multisystem inflammatory syndrome; MRE, myocarditis‐related events (within 30 days included all‐cause death, cardiogenic shock, cardiac arrest, ventricular arrhythmias or complete AV block). Abstract Aims Acute myocarditis (AM) is a rare but severe disease affecting patients of all ages. Large multicentric studies comparing children and adults are
Clément Karsenty   +25 more
wiley   +1 more source

The effects of a quality improvement project to reduce caesarean sections in selected private hospitals in Brazil. [PDF]

open access: yesReprod Health
do Carmo Leal M   +16 more
europepmc   +1 more source

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Heart failure (HF) is one of today's leading public health issues worldwide. The sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germany. However, real‐world data are limited.
Matthias Paul   +7 more
wiley   +1 more source

Real‐world use of guideline‐directed therapy for heart failure: Insights from the Danish Heart Failure Registry

open access: yesESC Heart Failure, EarlyView.
Our study examined the real‐world implementation of guideline‐directed medical therapy (GDMT) and its association with mortality and hospitalization in 46 816 patients with heart failure with reduced ejection fraction (HFrEF) from the Danish Heart Failure Registry (2008–2022).
Inge Schjødt   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy